Methoxetamine: Difference between revisions
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
= General Information = | = General Information = | ||
Methoxetamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of [[Ketamine]] and [[PCP]]. It was first publicly reported in 2010. Some say it's similar to Ketamine or high | Methoxetamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of [[Ketamine]] and [[PCP]]. It was first publicly reported in 2010. Some say it's similar to Ketamine or high doses of DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed specifically for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDA receptor antagonist and unlike ketamine also acts as Serotonin Reuptake Inhibitor. The N-Ethyl group on this compound increases potency. | ||
= Dosage = | = Dosage = | ||
Revision as of 16:45, 20 July 2014
General Information
Methoxetamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of Ketamine and PCP. It was first publicly reported in 2010. Some say it's similar to Ketamine or high doses of DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed specifically for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDA receptor antagonist and unlike ketamine also acts as Serotonin Reuptake Inhibitor. The N-Ethyl group on this compound increases potency.
Dosage
| Threshold | 5-20mg |
| Low | 10-30mg |
| Common | 40-60mg |
| Strong | 50-100mg+ |
| Threshold | 5-15mg |
| Low | 15-30mg |
| Common | 30-50mg |
| Strong | 50-75mg |
| Hole | 75-100mg+ |
| Threshold | 5-10mg |
| Low | 10-20mg |
| Common | 40-60mg |
| Strong | 60-75mg |
| Hole | 75-100mg+ |
Duration
| Onset | 30-60 minutes |
| Total | 3-6 hours |
| After-effects | 2-48 hours (dose-dependent) |
| Onset | 5-40 minutes |
| Total | 3-6 hours |
| After-effects | 2-48 hours (dose-dependent) |
| Onset | 15-45 minutes |
| Total | 3-6 hours |
| After-effects | 2-48 hours (dose-dependent) |
Effects
Positive
- Euphoria, mood lift
- Sense of calm and serenity
- Vivid recall of past memories and dreams
- Closed- and open-eye visuals (common)
- Out-of-body experience (less intense then ketamine)
Neutral
- Distortion or loss of sensory perceptions (common)
- Dissociation of mind from body
- Sweating
- Analgesia, numbness
- Significant change in perception of time
- Increase in heart rate
- Confusion, disorientation
Negative
- Risk of psychological dependency
- Nasal discomfort upon insufflation
- Blacking out and forgetting one has taken a drug
- Discomfort, pain or numbness at injection site (with IM)
- Severe confusion, disorganised thinking
- Vertigo, spinning sensation (risk of injury)
- Nausea, vomiting
- Susceptibility to accidents (from uncoordination and change in perception of body and time)
- Severe dissociation, depersonalisation
- Loss of consciousness
- Depression of heart rate and respiration (risk increases with increased dose or when combined with depressants)
Harm Reduction
- Avoid driving at all costs.
- Avoid walking or moving around in general if you are on a medium to hole dose.
- Taking this on a non-empty substance could lead to nausea.